18F-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy

Clinical Cancer Research

Volumn 18, Issue 7, 2012, Pages 2024-2031

  Herrmann, Ken ^a   Benz, Matthias R ^a   Czernin, Johannes ^a   Allen Auerbach, Martin S ^a   Tap, William D ^a   Dry, Sarah M ^a   Schuster, Tibor ^b   Eckardt, Jeff J ^a   Phelps, Michael E ^a   Weber, Wolfgang A ^a,c   Eilber, Fritz C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOFT TISSUE SARCOMA; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; TIME OF DEATH; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PROGNOSIS; RADIOGRAPHY; SARCOMA; SCINTISCANNING; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SARCOMA; TIME FACTORS; YOUNG ADULT;

EID: 84859376797     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2139     Document Type: Article

References (35)

1. Reynoso D, Subbiah V, Trent JC, Guadagnolo BA, Lazar AJ, Benjamin R, et al. Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol 2010;101:327-33.
2. National Cancer Institute. Cancer topics. Bethesda (MD): National Cancer Institute. [cited 2011 Jul 1]. Available from: http://www.cancer.gov/ cancertopics/pdq/treatment/adult-soft-tissue-sarcoma/HealthProfessional/page1.
3. Collin C, Godbold J, Hajdu S, Brennan M. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987;5:601-12. (Pubitemid 17062498)
4. Gaynor JJ, Tan CC, Casper ES, Collin CF, Friedrich C, Shiu M, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992;10:1317-29.
5. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008;14:715-20. (Pubitemid 351231152)
6. Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009;15:2856-63.
7. Edmonson JH, Petersen IA, Shives TC, Mahoney MR, Rock MG, Haddock MG, et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony- stimulating factor. Cancer 2002;94:786-92. (Pubitemid 34132309)
8. Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, et al. Treatment-induced pathologic necrosis: a predictor of localrecurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001; 19:3203-9. (Pubitemid 32591437)
9. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:3144-50. (Pubitemid 47218064)
10. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, et al. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 2010;51:551-8.
11. Tateishi U, Kawai A, Chuman H, Nakatani F, Beppu Y, Seki K, et al. PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med 2011;36:526-32.
12. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18FFDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059-66. (Pubitemid 46939960)
13. Beyer T, Antoch G, Muller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004;45 Suppl 1:25S-35S.
14. Halpern BS, Dahlbom M, Auerbach MA, Schiepers C, Fueger BJ, Weber WA, et al. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med 2005;46:603-7. (Pubitemid 41716404)
15. Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med 2004;45:797-801. (Pubitemid 47618559)
16. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998;25:2046-53.
17. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 2008;49:1038-46. (Pubitemid 351948010)
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
19. Saville DJ. Multiple comparison procedures: the practical solution. Am Stat 1990;44:174-80.
20. Baldini EH, Goldberg J, Jenner C, Manola JB, Demetri GD, Fletcher CD, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999;17:3252-9. (Pubitemid 29470660)
21. Heslin MJ, Woodruff J, Brennan MF. Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management. J Clin Oncol 1996;14:473-8. (Pubitemid 26051010)
22. Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol 1996; 14:1201-8. (Pubitemid 26105527)
23. Dudeck O, Zeile M, Pink D, Pech M, Tunn PU, Reichardt P, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 2008;27:1109-13. (Pubitemid 351614624)
24. Viglianti BL, Lora-Michiels M, Poulson JM, Lan L, Yu D, Sanders L, et al. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res 2009;15:4993-5001.
25. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53. (Pubitemid 46291806)
26. Strobel K, Dummer R, Steinert HC, Conzett KB, Schad K, Lago MP, et al. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumor marker S-100B. Eur J Nucl Med Mol Imaging 2008;35:1786-95.
27. Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682-8. (Pubitemid 36612950)
28. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7. (Pubitemid 46606307)
29. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8. (Pubitemid 41103602)
30. Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining long term outcomes of rectal cancer. J Am Coll Surg 2004;199:1-7. (Pubitemid 38813288)
31. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-9. (Pubitemid 32187807)
32. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339-48. (Pubitemid 40129294)
33. Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW, Hoetjes NJ, et al. Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging 2011;38:832-42.
34. Herrmann K, Bundschuh RA, Rosenberg R, Schmidt S, Praus C, Souvatzoglou M, et al. Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI. Mol Imaging Biol 2011;13:1011-9.
35. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797-805. (Pubitemid 47308659)